Related Articles
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced ApcMIN/+ mouse model
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo
Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)